Tecentriq

(Atezolizumab)

ApprovedMonoclonal antibody

Atezolizumab is used to treat certain types of cancer, including lung cancer, bladder cancer, and breast cancer, by helping the body's immune system recognize and fight cancer cells.[2] Tecentriq is currently approved and in use across 153 indications[4].[1]

Tecentriq is one of 1573 monoclonal antibody programs targeting Melanoma. It is currently in Approved.

153

Indications

682

Total Trials

Active Trials

1,572

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

MelanomaTerminated

Small Cell Lung CancerCompleted

Soft Tissue SarcomaRecruiting

Liver TransplantActive, not recruiting

Cervical CancerCompleted

Squamous Cell CarcinomaActive, not recruiting

Triple-Negative Breast CancerCompleted

Biliary Tract CancerActive, not recruiting

Advanced Solid TumorsCompleted

TreatmentActive, not recruiting

MelanomaPhase 3

Terminated

Small Cell Lung CancerPhase 3

Completed

Soft Tissue SarcomaPhase 2

Recruiting

Liver TransplantApproved

Active, not recruiting

Cervical CancerPhase 2

Completed

Squamous Cell CarcinomaPhase 3

Active, not recruiting

Triple-Negative Breast CancerPhase 3

Completed

Biliary Tract CancerPhase 2

Active, not recruiting

Advanced Solid TumorsPhase 2

Completed

TreatmentPhase 3

Active, not recruiting

Showing 10 of 153 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Approved

35 2

Adenocard

Astellas

Preclinical

2 3

Lexiscan

Astellas

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

Spravato

WWim Janssens

Preclinical

2 7

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Tricor

JJagotec

Preclinical

1 9

Nubain

AAultman Health Foundation

Preclinical

1 10

Feraheme

AAzurity Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Cutaneous Melanoma

NCT04020809

Phase 3Active, not recruiting

Mcrpc

NCT04446117

Phase 2Active, not recruiting

Immunotherapy

NCT05798663

Phase 1Active, not recruiting

Pancreatic Cancer

NCT04161755

Phase 1Active, not recruiting

Cancer

NCT02862275

Post-ApprovalRecruiting

Infusion

NCT06031233

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer25 trials

A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)

Terminated· Incyte logo

Incyte·Phase 1·NCT02298153·29 enrolled

A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 2·NCT04426825·23 enrolled

The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy

Completed· Roche logo

Roche··NCT03559647·358 enrolled

Show 22 more trials

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT04214262·480 enrolled

Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

Completed· Roche logo

Roche·Phase 3·NCT04471428·366 enrolled

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Terminated· Roche logo

Roche·Phase 2·NCT04832854·50 enrolled

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

Recruiting·IIntergroupe Francophone de Cancerologie Thoracique·Phase 3·NCT06908993·133 enrolled

A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 4·NCT03285763·619 enrolled

A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 2·NCT02031458·667 enrolled

A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 2·NCT03563716·135 enrolled

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Completed· Roche logo

Roche·Phase 3·NCT02409342·572 enrolled

A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Completed· Roche logo

Roche·Phase 2·NCT01846416·138 enrolled

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Completed· Roche logo

Roche·Phase 3·NCT03456063·453 enrolled

A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

Completed· Roche logo

Roche·Phase 2·NCT02927301·181 enrolled

A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy

Completed· Roche logo

Roche·Phase 3·NCT02813785·565 enrolled

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

Completed· Roche logo

Roche·Phase 3·NCT03191786·453 enrolled

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Active, not recruiting·NNational Taiwan University Hospital·Phase 2·NCT04147351·22 enrolled

Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer

Unknown status·YYonsei University·Phase 2·NCT05034055·45 enrolled

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Active, not recruiting·UUniversity of Southern California·Phase 2·NCT05340309·5 enrolled

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT02367781·723 enrolled

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT02366143·1,202 enrolled

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT04989283

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Completed· Roche logo

Roche·Phase 3·NCT02657434·578 enrolled

Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer

Completed· Regeneron logo

Regeneron·Phase 1·NCT03438318·29 enrolled

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Recruiting·—·Phase 1/2·NCT04691817·28 enrolled

Hepatocellular Carcinoma15 trials

Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Terminated·—·Phase 2·NCT04541173·6 enrolled

Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma

Recruiting·—·Phase 2·NCT06133062·45 enrolled

A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

Active, not recruiting·HHoward S Hochster·Phase 2·NCT04829383·50 enrolled

Show 12 more trials

Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma

Recruiting·—·Phase 2·NCT06339424·45 enrolled

A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization

Completed· Roche logo

Roche··NCT06503250·113 enrolled

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

Completed·FFederation Francophone de Cancerologie Digestive·Phase 2/3·NCT05665348·229 enrolled

SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT05093608·2 enrolled

Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma

Completed·SSun Yat-sen University··NCT06199297·188 enrolled

Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Unknown status·—··NCT05173298·100 enrolled

Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy

Completed·—··NCT05197504·166 enrolled

β-alanine in the Treatment of Advanced Hepatocellular Carcinoma

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07317414·158 enrolled

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Suspended·NNorthwestern University·Phase 2·NCT05620771·84 enrolled

Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection

Not yet recruiting·UUniversity of Geneva, Switzerland·Phase 3·NCT07461675·30 enrolled

Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma

Terminated·UUniversity Hospital, Grenoble·Phase 2·NCT05448677·3 enrolled

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

Recruiting·IInova Health Care Services·Phase 2·NCT06789757·19 enrolled

Breast Cancer15 trials

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

Terminated· Roche logo

Roche·Phase 3·NCT04740918·96 enrolled

A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer

Terminated·—·Phase 2·NCT04690855·1 enrolled

Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Withdrawn·MMayo Clinic·Phase 1·NCT04249167

Show 12 more trials

Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer

Completed·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT03464942·54 enrolled

Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy

Terminated·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT05180006·33 enrolled

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT03199885·190 enrolled

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Active, not recruiting·FFox Chase Cancer Center·Phase 2·NCT03125928·16 enrolled

Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

Active, not recruiting·FFondazione Michelangelo·Phase 3·NCT03595592·650 enrolled

Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer

Completed·FFondazione Policlinico Universitario Agostino Gemelli IRCCS··NCT05609903·52 enrolled

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT03197935·333 enrolled

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

Completed· Roche logo

Roche·Phase 3·NCT03125902·653 enrolled

Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer

Active, not recruiting·SSOLTI Breast Cancer Research Group·Phase 2·NCT04759248·55 enrolled

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Recruiting·GGerman Cancer Research Center·Phase 2·NCT05332561·240 enrolled

Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients

Recruiting·EEuropean Institute of Oncology·Phase 2·NCT06690840·45 enrolled

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT02605915·98 enrolled

Small Cell Lung Cancer7 trials

A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 3·NCT04028050·155 enrolled

Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer

Terminated·UUniversity of Washington·Phase 1/2·NCT05191797·3 enrolled

A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Terminated· Roche logo

Roche·Phase 1·NCT04422210·2 enrolled

Show 4 more trials

A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer

Terminated· Roche logo

Roche·Phase 2·NCT04308785·24 enrolled

Immunotherapy as Second-line in Patient With Small Cell Lung Cancer

Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT03059667·73 enrolled

Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT04462276·68 enrolled

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Completed· Roche logo

Roche·Phase 3·NCT02763579·503 enrolled

Immunotherapy7 trials

Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN

Completed·UUniversity Hospital, Essen·Phase 2·NCT04939480·20 enrolled

Liver Directed RT + Chemo-immunotherapy for ES-SCLC

Terminated·—·Phase 2·NCT04923776·2 enrolled

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Unknown status·FFondazione per la Medicina Personalizzata·Phase 2·NCT04591431·400 enrolled

Show 4 more trials

Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

Active, not recruiting·AAlliance Foundation Trials, LLC.·Phase 2·NCT05798663·178 enrolled

Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab

Recruiting·RRegina Elena Cancer Institute·Phase 2·NCT06771518·37 enrolled

SIRT and Peri-immunotherapy : a New Concept

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris··NCT06971237·60 enrolled

Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)

Not yet recruiting·—·Phase 3·NCT06719336·182 enrolled

87 more indications

Urothelial Carcinoma5 trials

A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection

Terminated· Roche logo

Roche·Phase 3·NCT02450331·809 enrolled

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT03513952·47 enrolled

A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

Completed· Roche logo

Roche·Phase 3·NCT02928406·1,004 enrolled

Show 2 more trials

Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT03208712·1 enrolled

Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma

Completed·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT04602078·82 enrolled

Triple-Negative Breast Cancer4 trials

A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT03101280·29 enrolled

Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer

Completed·OOslo University Hospital·Phase 2·NCT03164993·68 enrolled

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT04584112·83 enrolled

Show 1 more trial

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Completed· Roche logo

Roche·Phase 3·NCT02425891·902 enrolled

Advanced Solid Tumors4 trials

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Completed· Roche logo

Roche·Phase 2·NCT04632992·252 enrolled

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Terminated·DDracen Pharmaceuticals, Inc.·Phase 1/2·NCT04471415·61 enrolled

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Completed· Roche logo

Roche·Phase 2·NCT02091141·673 enrolled

Show 1 more trial

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Completed·AAdlai Nortye Biopharma Co., Ltd.·Phase 1·NCT04975958·47 enrolled

Bevacizumab4 trials

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Terminated·YYale University·Phase 2·NCT05776875·3 enrolled

The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

Completed·MMedical College of Wisconsin·Phase 2·NCT03694262·30 enrolled

Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

Completed·—··NCT04862949·131 enrolled

Show 1 more trial

Atezolizumab Plus Bevacizumab in First Line NSCLC Patients

Completed·FFundación GECP·Phase 2·NCT03836066·41 enrolled

Renal Cell Carcinoma3 trials

A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

Terminated· Roche logo

Roche·Phase 3·NCT04338269·522 enrolled

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

Completed· Roche logo

Roche·Phase 2·NCT01984242·305 enrolled

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

Completed· Roche logo

Roche·Phase 3·NCT02420821·915 enrolled

Prostate Cancer3 trials

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Completed· Roche logo

Roche·Phase 1·NCT02814669·45 enrolled

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT04272645

Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Completed·UUniversity of Hawaii·Phase 1·NCT03024216·37 enrolled

Lung Cancer3 trials

Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer

Active, not recruiting·NNorwegian University of Science and Technology·Phase 2·NCT03540420·212 enrolled

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Recruiting·VVanderbilt-Ingram Cancer Center·Phase 1/2·NCT05501665·25 enrolled

Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

Active, not recruiting·IIntergroupe Francophone de Cancerologie Thoracique·Phase 3·NCT03977194·510 enrolled

Colorectal Cancer3 trials

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Completed· Amgen logo

Amgen·Phase 1·NCT03256344·36 enrolled

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Active, not recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT05999812·22 enrolled

Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin

Active, not recruiting·AAIO-Studien-gGmbH·Phase 2·NCT05118724·80 enrolled

Metastatic Solid Tumors3 trials

A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02304393·140 enrolled

Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

Terminated· Roche logo

Roche·Phase 2·NCT03386721·256 enrolled

A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT04303858·189 enrolled

Treatment3 trials

The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL

Active, not recruiting·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 2·NCT03463057·109 enrolled

The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients

Unknown status·FFirst Affiliated Hospital of Zhejiang University··NCT03228368·10 enrolled

Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice

Terminated· Roche logo

Roche·Phase 2/3·NCT05694013·49 enrolled

Efficacy and Safety3 trials

Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

Recruiting·—·Phase 2·NCT07239245·30 enrolled

Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC

Not yet recruiting·FFuzhou General Hospital··NCT07093762·35 enrolled

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Active, not recruiting· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 3·NCT05468489·200 enrolled

Locally Advanced or Metastatic Solid Tumors3 trials

Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT01988896·153 enrolled

A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT01688206·132 enrolled

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT01375842·661 enrolled

Bladder Cancer3 trials

Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)

Active, not recruiting·FFundacion Oncosur·Phase 1·NCT04134000·40 enrolled

Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

Active, not recruiting·UUNICANCER·Phase 3·NCT03799835·517 enrolled

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

Completed· Roche logo

Roche·Phase 3·NCT02302807·931 enrolled

Endometrial Cancer3 trials

Atezolizumab Trial in Endometrial Cancer - AtTEnd

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 3·NCT03603184·549 enrolled

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT05542407·58 enrolled

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Recruiting·AAlliance Foundation Trials, LLC.·Phase 1/2·NCT04486352·148 enrolled

Liver Cancer3 trials

A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev

Active, not recruiting·JJia Fan·Phase 3·NCT04649489·501 enrolled

Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant

Recruiting·UUniversity Health Network, Toronto·Phase 1/2·NCT06725121·48 enrolled

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)

Recruiting·MMichael Dill·Phase 2·NCT05690048·48 enrolled

Gastric Cancer2 trials

Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer

Withdrawn·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03818997

WaKING: Wnt and checKpoint INhibition in Gastric Cancer

Active, not recruiting·RRoyal Marsden NHS Foundation Trust·Phase 1/2·NCT04166721·52 enrolled

Pancreatic Cancer2 trials

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

Completed·LLokon Pharma AB·Phase 1/2·NCT02705196·51 enrolled

Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04161755·29 enrolled

Follicular Lymphoma2 trials

Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03465891·2 enrolled

A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT02631577·38 enrolled

Cervical Cancer2 trials

Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

Active, not recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT03340376·48 enrolled

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Withdrawn·NNykode Therapeutics ASA·Phase 2·NCT06099418

Diffuse Large B-Cell Lymphoma2 trials

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT02220842·96 enrolled

A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 1/2·NCT02729896·36 enrolled

Metastatic Colorectal Cancer2 trials

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting·SSeattle Project Corporation·Phase 2/3·NCT05141721·700 enrolled

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

Recruiting·GGruppo Oncologico del Nord-Ovest·Phase 3·NCT06733038·238 enrolled

Lymphoma2 trials

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

Completed·OOrphAI Therapeutics·Phase 1·NCT02594384·62 enrolled

A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Withdrawn· Roche logo

Roche·Phase 1·NCT03369964

Ovarian Cancer2 trials

Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

Completed·GGrupo Español de Investigación en Cáncer de Ovario·Phase 3·NCT03598270·417 enrolled

ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

Completed·AARCAGY/ GINECO GROUP·Phase 3·NCT02891824·614 enrolled

Melanoma2 trials

Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC

Terminated·UUniversity Hospital Tuebingen·Phase 2·NCT02303951·47 enrolled

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

Active, not recruiting·UUnknown Sponsor·Phase 2·NCT04722575·95 enrolled

Pilot Study1 trial

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

Terminated·PPeter MacCallum Cancer Centre, Australia·N/A·NCT04801966·3 enrolled

Squamous Cell Carcinoma1 trial

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT05459129·12 enrolled

Microsatellite Instability1 trial

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Recruiting·CCancer Research UK·Phase 2/3·NCT05770102·30 enrolled

Skin Cancer1 trial

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Terminated·NNeoImmuneTech·Phase 1/2·NCT03901573·31 enrolled

Cancer1 trial

Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02862275·40 enrolled

mCRPC1 trial

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Active, not recruiting·EExelixis·Phase 3·NCT04446117·575 enrolled

Metastatic Tumors1 trial

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Completed· Roche logo

Roche·Phase 1·NCT03289962·272 enrolled

Cholangiocarcinoma1 trial

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Terminated·HHalozyme Therapeutics·Phase 1·NCT03267940·85 enrolled

Neoadjuvant Therapy1 trial

Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

Recruiting·HHunan Province Tumor Hospital·Phase 2·NCT05295212·120 enrolled

Adult1 trial

Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants

Terminated·SSynlogic·Phase 1·NCT04167137·32 enrolled

Immune Checkpoint Inhibitors1 trial

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Completed·FFate Therapeutics·Phase 1·NCT03841110·37 enrolled

Refractory Solid Tumors1 trial

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT04796012·23 enrolled

NSCLC1 trial

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

Completed·SSwiss Cancer Institute·Phase 2·NCT04480372·68 enrolled

Patients With Advanced Solid Tumors1 trial

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Withdrawn·RRain Oncology Inc·Phase 1/2·NCT06090318

Advanced Cancers1 trial

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT04902040·19 enrolled

Neuroendocrine Carcinoma1 trial

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

Recruiting·NNanjing Leads Biolabs Co.,Ltd·Phase 1/2·NCT06157827·178 enrolled

Carboplatin1 trial

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Unknown status·SSamsung Medical Center·Phase 3·NCT03991403·228 enrolled

Radiotherapy1 trial

Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

Active, not recruiting·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT04186013·39 enrolled

Stereotactic Body Radiation Therapy1 trial

Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)

Unknown status·CCentre Georges Francois Leclerc·Phase 1·NCT05259319·92 enrolled

Asymptomatic Myeloma1 trial

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

Terminated·YYale University·Phase 1·NCT02784483·2 enrolled

Efficacy1 trial

Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]

Completed·—·Phase 4·NCT04059887·100 enrolled

Glioblastoma1 trial

Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial

Recruiting·—·Phase 2·NCT07263438·59 enrolled

Esophageal Squamous Cell Carcinoma1 trial

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Completed·NNational Taiwan University Hospital·Phase 2·NCT05007613·24 enrolled

Glioma1 trial

D2C7-IT With Atezolizumab for Recurrent Gliomas

Active, not recruiting·DDarell Bigner·Phase 1·NCT04160494·18 enrolled

Penile Cancer1 trial

PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study

Completed·TThe Netherlands Cancer Institute·Phase 2·NCT03686332·32 enrolled

Cancer of Unknown Primary Site1 trial

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

Completed· Roche logo

Roche·Phase 2·NCT03498521·529 enrolled

Gastrointestinal1 trial

Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors

Completed· Roche logo

Roche·Phase 1·NCT02876224·51 enrolled

CDK4/6 Inhibitor1 trial

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

Completed·GG1 Therapeutics, Inc.·Phase 2·NCT03041311·107 enrolled

Cutaneous Melanoma1 trial

Neoadjuvant Atezolizumab in Cutaneous Melanoma

Active, not recruiting·TThe Methodist Hospital Research Institute·Phase 1·NCT04020809·20 enrolled

Papilloma1 trial

Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)

Completed·—·Phase 2·NCT03946358·47 enrolled

Infusion1 trial

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Recruiting·IIsala·Phase 4·NCT06031233·679 enrolled

Biliary Tract Cancer1 trial

A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

Completed· Roche logo

Roche·Phase 2·NCT04677504·162 enrolled

Abemaciclib1 trial

Abemaciclib With or Without Atezolizumab for mCRPC

Active, not recruiting·—·Phase 2·NCT04751929·19 enrolled

Genitourinary Cancer1 trial

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT03115801·6 enrolled

Locally Advanced or Metastatic NSCLC1 trial

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Active, not recruiting·NNeoImmuneTech·Phase 2·NCT04984811·83 enrolled

Mucosal Melanoma1 trial

Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Completed· Roche logo

Roche·Phase 2·NCT04091217·43 enrolled

Multiple Myeloma1 trial

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Completed· Roche logo

Roche·Phase 1·NCT02431208·85 enrolled

Effectiveness1 trial

The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study

Completed·SSun Yat-sen University·N/A·NCT07272265·300 enrolled

Brachytherapy1 trial

TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Recruiting·TThird Affiliated Hospital, Sun Yat-Sen University·N/A·NCT05984511·234 enrolled

Portal vein thrombosis1 trial

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Recruiting·—·Phase 2·NCT06823375·40 enrolled

Chemotherapy1 trial

Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab

Recruiting·SSun Yat-sen University·Phase 2·NCT07192185·30 enrolled

Malignant Pleural Mesothelioma1 trial

Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

Recruiting·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 3·NCT04996017·162 enrolled

Trial1 trial

The Drug Rediscovery Protocol (DRUP Trial)

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT02925234·1,550 enrolled

MPA1 trial

Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy

Terminated·PPalleos Healthcare GmbH·Phase 2·NCT04770272·442 enrolled

Macrovascular Invasion1 trial

Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion

Recruiting·—·Phase 2·NCT05992220·138 enrolled

Colorectal Adenocarcinoma1 trial

A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

Completed· Roche logo

Roche·Phase 3·NCT02788279·363 enrolled

Fecal Microbiota Transplantation1 trial

Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

Recruiting·IIRCCS Azienda Ospedaliero-Universitaria di Bologna·Phase 2·NCT07276100·15 enrolled

Non-squamous NSCLC1 trial

Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC

Recruiting·UUniversity Hospital Heidelberg·Phase 2·NCT04865250·20 enrolled

Richter Transformation1 trial

ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruiting·NNiguarda Hospital·Phase 2·NCT04082897·28 enrolled

Unresectable1 trial

Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)

Recruiting·TTuen Mun Hospital·Phase 2/3·NCT07293468·106 enrolled

Unknown status·HHospices Civils de Lyon·Phase 2·NCT04739202·60 enrolled

Radiation Therapy1 trial

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Terminated·RRutgers, The State University of New Jersey·Phase 1·NCT04081688·16 enrolled

Anal Carcinoma1 trial

Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)

Recruiting·GGrupo Espanol Multidisciplinario del Cancer Digestivo·Phase 2·NCT05661188·45 enrolled

Metastatic1 trial

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Terminated·AAffimed GmbH·Phase 1/2·NCT05109442·112 enrolled

Immune1 trial

Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC

Completed·WWashington University School of Medicine·Phase 2·NCT03689855·21 enrolled

PD-L1 Antibody1 trial

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

Completed· Roche logo

Roche·Phase 3·NCT03016312·759 enrolled

Advanced1 trial

Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients

Recruiting·OOmico·Phase 2·NCT06003621·96 enrolled

First-line1 trial

A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

Not yet recruiting·BBiotheus Inc.·Phase 1/2·NCT06584071·140 enrolled

Toxicity1 trial

Microbiome Immunotherapy Toxicity and Response Evaluation

Unknown status·CCCTU- Cancer Theme··NCT04107168·1,800 enrolled

Rare Tumor1 trial

PLATFORM Study of Precision Medicine for Rare Tumors

Recruiting·—·Phase 2·NCT04423185·770 enrolled

Esophageal Cancer1 trial

PDL-1 Targeting in Resectable Oesophageal Cancer

Completed·—·Phase 2·NCT03087864·40 enrolled

Regulatory

FDA Approval Timeline[5]

May 18, 2016

Tecentriq

BLA 761034

May 18, 2016

TECENTRIQ

BLA BLA761034

Sources

References

[1]
ClinicalTrials.gov — 682 trial records for Atezolizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Tecentriq drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Atezolizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Atezolizumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA 761034). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: PD-L1 Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Roche